Gordon Fox • July 4, 2022
Training and Experience Count: Myectomy is Safest at High-Volume Centers
Myectomies at hospitals averaging more than 10 procedures per year led to fewer deaths and complications than at other hospitals.

Large study of US myectomies

Myectomy is safest at high-volume centers. A study accepted in The Annals of Thoracic Surgery provides new evidence of this.

Kimberly A. Holst and her collaborators (2022) examined nearly 6,000 US myectomies reported from 2012 to 2019. Their data came from a database compiled by the Society of Thoracic Surgeons.

Mortality and post-operative risks lowest in high-volume centers

The researchers found that the chance of death was lowest in hospitals that performed more of the surgeries. But they also found that the risk of serious complications was much lower in these hospitals. The complications they studied included perforation of the interventricular septum and complete heart block.

Furthermore, those high-volume hospitals replaced mitral valves less often as part of the procedure.

Myectomy is safest in high-volume centers

These results strengthen the conclusions suggested by Kim et al. (2016) , that septal myectomy is safest at high-volume centers.

Literature cited

Holst, K. A., H. V. Schaff, N. G. Smedira, E. B. Habermann, C. N. Day, V. Badhwar, H. Takayama, P. M. McCarthy, and J. A. Dearani. 2022. Impact of Hospital Volume on Outcomes of Septal Myectomy for Hypertrophic Cardiomyopathy. The Annals of Thoracic Surgery , in press.

Kim, L. K., R. V. Swaminathan, P. Looser, R. M. Minutello, S. C. Wong, G. Bergman, S. S. Naidu, C. L. F. Gade, K. Charitakis, H. S. Singh, and D. N. Feldman. 2016. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011. J AMA Cardiology 1:324–332.

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts